南华生物医药股份有限公司第十二届董事会第五次会议决议公告

Group 1 - The company held its 12th Board of Directors' fifth meeting on November 14, 2025, via communication methods, with 5 out of 7 directors participating in the vote [2] - The board approved a proposal for the transfer of certain accounts receivable to Hunan Caixin Asset Management Co., Ltd. to optimize the company's financial structure and accelerate capital recovery [2] - The transaction was conducted at a fair market price and will not affect the company's business independence, benefiting the long-term interests of the company and all shareholders [2] Group 2 - The board meeting's resolution was signed and sealed by the participating directors, and the independent directors' special meeting resolution was also documented [4] - The company authorized its management to handle all matters related to the transaction, including signing legal documents and collecting transaction proceeds [2]